Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 94

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 94
---
2024, unanimously determined that it is expedient and
in the best interests of Aadi and its stockholders, and advisable, fair to, and in the best interests of, Aadi and its stockholders, to enter into the Divestiture Agreement and approved, adopted and declared advisable the Divestiture Agreement and
the Divestiture and the other transactions contemplated by the Divestiture Agreement. Aadi’s board of directors also unanimously resolved that the Divestiture Agreement be submitted for consideration by Aadi’s stockholders at a special
meeting of stockholders and recommended that Aadi’s stockholders vote to approve the Divestiture Agreement and the Divestiture Agreement. In reaching the foregoing determinations and recommendation, Aadi’s board of directors consulted with
members of Aadi’s management team and its outside financial and legal advisors at various times and considered a number of

- 60 -

potentially supportive factors in its deliberations, including the following principal factors (not in any relative order of importance) that Aadi’s board of directors believes support such determinations and recommendation.

| • |     | information concerning Aadi’s current and future business, financial performance and condition, assets and 
 liabilities, operations, risks, management and competitive position;                                       |

| • |     | current financial market conditions and historical market prices, volatility and trading information with respect 
 to the common stock of Aadi;                                                                                      |

| • |     | Aadi’s consideration of possible strategic alternatives, including entering into a transaction with another 
 party or liquidating the assets of Aadi;                                                                    |

| • |     | the cessation of the PRECISION1 trial in light of the analysis by the Independent Data Monitoring Committee that       
 demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval; |

| • |     | the consideration to be received by Aadi in the Divestiture; |

| • |     | the terms of the Divestiture Agreement, including the conditions to closing the Divestiture set forth therein and                                                                                                                          
 the terms governing Aadi’s ability to solicit and evaluate competing acquisition proposals or other proposals for competing strategic transactions (including the ability of Aadi’s board of directors to withdraw its recommendation that 
 stockholders vote in favor of the Divestiture if Aadi’s board of directors receives a superior proposal, subject to certain additional provisions and exceptions);                                                                         |

| • |     | the extensive process undertaken by Aadi’s board of directors and Leerink Partners to identify and evaluate